Diabetic Foot Ulcer Clinical Trial
— MATHCOWOfficial title:
A Prospective Cohort Survey of Foot and Leg Chronic Wounds Followed up to 20 Weeks After Initiation of CACIPLIQ20® add-on to Optimal Local Care
CACIPLIQ20® is currently a class III CE marked medical device available in various European and non-European countries, and currently primarily used in managing hard-to-heal wounds. This study is a prospective and standardized recording of patients' data followed in real-life conditions to appreciate the benefits of a therapeutic strategy including CACIPLIQ20® use. It also aims at collecting data to follow-up the device's efficacy and safety and estimate its cost-effectiveness.
Status | Recruiting |
Enrollment | 200 |
Est. completion date | July 2024 |
Est. primary completion date | July 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | General Inclusion Criteria: - Patients justifying a treatment with CACIPLIQ20® according to a care provider. - Patients presenting with a chronic wound that has not shown signs of improvement following treatment for at least 6 months prior to inclusion into the study. - Adult patients of either gender aged at least 18 and without upper limit for age. - Patients having received a full written and oral information about study conduct and objectives and having given a written consent to participate according to local regulations. - Patients being seen as outpatients and for whom no hospitalization is expected/planned in the 6 forthcoming weeks. - Patients who can and are willing to be followed by a study investigator for the duration of the study. - Patients benefiting from a valid health insurance or social security coverage. Target Wound Inclusion Criteria: - Current wound that has not been previously treated with CACIPLIQ20®. - Target wound located below the knee. - Target wound is either: 1. a leg ulceration predominantly of venous origin (no ischemia as previously defined) with an area >10 cm² and/or a duration of at least 5 months, 2. a leg ulceration of any size or duration, with a documented ischemic lower limb problem, 3. a foot ulceration of any size or duration, documented as a diabetic foot ulceration (DFU). - If more than one wound is present and eligible, investigators will be required to select one as the target wound for this study. This wound should be the largest one. If wounds are of similar size, the ulceration considered by the investigator as the worst will be selected. Exclusion Criteria: - Female patients who are pregnant, or lactating. - Bedridden patients unable to spend at least one hour per day sitting in a chair. - Patients suffering from severe cognitive problems precluding any voluntary participation to the study. - Patients with, according to investigator's opinion, a very poor life expectancy. - Patients with leg or foot ulcerations which are not of venous, arterial or diabetic origin (e.g. Martell's ulcer and related ulcers, pressure ulcers, traumatic wounds or burns) - Patients whose target wound is located on an amputation stump. - Patients presenting with a fungating wound at the time of inclusion. - Patients in an emergency situation and unable to give consent. - Patients intolerant to one of the study device components or to heparinoids. |
Country | Name | City | State |
---|---|---|---|
France | Réseau Cicat-Occitanie | Montpellier |
Lead Sponsor | Collaborator |
---|---|
Organ, Tissue, Regeneration, Repair and Replacement |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of wound closure | Wound closure defined as a 100% re-epithelialization, including:
A confirmed complete closure (CCC), defined as a wound closure notified by investigator and confirmed by an independent reviewer when analysing wound photos. A possible complete closure (PCC), defined as a wound closure notified by investigator without confirmation by the independent reviewer (either no photo or photo of too poor quality or no unambiguous confirmation). The primary endpoint is the sum of CCC and PCC. |
Within 20 weeks after treatment initiation | |
Secondary | Rate of adverse events (AEs) related to CACIPLIQ20® use | Rate of adverse events (AEs) occurring during the study course including serious and non-serious AEs, anticipated or unanticipated AEs, related to CACIPLIQ20® use, according to investigators' opinion. | From baseline to wound closure or 20 weeks after treatment initiation | |
Secondary | Rate of device deficiencies (DDs) | Rate of device deficiencies (DDs) occurring during the study course including anticipated or unanticipated DDs. | From baseline to wound closure or 20 weeks after treatment initiation | |
Secondary | Rate of wound closure according to the type of closure (CCC, PCC) and according to the nature of the treated wounds (Venous Leg Ulcers, Arterial Ulcers and Diabetic Foot Ulcers). | Within 20 weeks after treatment initiation | ||
Secondary | Time to wound closure | Within 20 weeks after treatment initiation | ||
Secondary | Changes in the Pain Visual Analogic Scale | Pain Visual Analogic Scale from 0 (no pain) to 10 (unbearable pain) | From baseline to wound closure or 20 weeks after treatment initiation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04497805 -
Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Wagner Grade II Foot Ulcers
|
Phase 2 | |
Withdrawn |
NCT03675269 -
Adjunctive Hyperbaric Oxygen Therapy (HBOT) for Lower Extermity Diabetic Ulcer:
|
N/A | |
Completed |
NCT04624516 -
Effect of Self-foot Exercise on the Incidence of Plantar Foot Diabetic Ulcer Recurrence
|
N/A | |
Not yet recruiting |
NCT06439667 -
VIRTUALLY SUPERVISED TELE-EXERCISE PLATFORM FOR ACCELERATING PLANTAR WOUND HEALING
|
||
Recruiting |
NCT05608187 -
Evaluating Safety and Biological Effect on Wound Healing of ILP100-Topical in Subjects With Diabetic Foot Ulcers
|
Phase 2 | |
Not yet recruiting |
NCT06278935 -
Lifestyle Tailored Offloading for Diabetic Foot Ulcers
|
N/A | |
Not yet recruiting |
NCT06437028 -
Evaluating the Efficacy of Perinatal Membrane Allografts for the Treatment of Diabetic Foot Ulcers.
|
N/A | |
Withdrawn |
NCT05024656 -
AmnioExcel® Plus vs SOC in the Management of Diabetic Foot Ulcers
|
N/A | |
Terminated |
NCT02202668 -
Transcutaneous Raman Spectroscope (TRS) Analyses of Diabetic Foot Ulcers
|
N/A | |
Terminated |
NCT01966380 -
Proof of Concept (Design Validation) in Patient With Hard to Heal Wounds Such as Pressure Ulcer, Diabetic Foot Ulcer and Leg Ulcer, Leia
|
Phase 2 | |
Completed |
NCT01951768 -
Efficacy and Safety of Garamycin® Sponge in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection
|
Phase 4 | |
Completed |
NCT01657474 -
Comparative Study of Two Application Regimens of Amniotic Membrane Wound Graft In the Management of Diabetic Foot Ulcers
|
N/A | |
Active, not recruiting |
NCT00389636 -
TheraGauze™ Alone and Regranex®Gel 0.01% Plus TheraGauze™ in the Treatment of Wagner Stage I Diabetic Foot Ulcers
|
N/A | |
Completed |
NCT01181440 -
Dermagraft(R) for the Treatment of Patients With Diabetic Foot Ulcers
|
Phase 3 | |
Enrolling by invitation |
NCT05888259 -
Plantar Pressure Distribution in Diabetic Foot Ulcer
|
N/A | |
Completed |
NCT04054804 -
Digital Foot Check by Using the D-Foot, a New Software
|
||
Not yet recruiting |
NCT05877378 -
Efficacy of PICO Single-use System in Chronic Ulcers
|
N/A | |
Recruiting |
NCT06037369 -
The Short Message-based Customized Standardized
|
N/A | |
Completed |
NCT03312595 -
Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU)
|
N/A | |
Recruiting |
NCT04564443 -
A Unique Micro Water Jet Technology Device Versus Standard Debridement in the Treatment of Diabetic Foot
|
N/A |